Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer

(2014) S. Misale et al.   Science Translational Medicine

Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

(2013) David Tougeron et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

(2013) M. Peeters et al.   CLINICAL CANCER RESEARCH

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

(2013) Muhammed Murtaza et al.   NATURE

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

(2013) Sarah-Jane Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

(2012) François-Clément Bidard et al.   CANCER AND METASTASIS REVIEWS

Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non-Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

(2012) E. A. Punnoose et al.   CLINICAL CANCER RESEARCH

Genome sequencing and cancer

(2012) Elaine R Mardis   CURRENT OPINION IN GENETICS & DEVELOPMENT

Translational genomics: The challenge of developing cancer biomarkers

(2012) J. D. Brooks   GENOME RESEARCH

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

(2012) Sandra Misale et al.   NATURE

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

(2012) Luis A. Diaz Jr et al.   NATURE

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

(2012) Clara Montagut et al.   NATURE MEDICINE

Evolution of the cancer genome

(2012) Lucy R. Yates et al.   NATURE REVIEWS GENETICS

Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

(2012) T. Forshew et al.   Science Translational Medicine

Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing

(2012) R. J. Leary et al.   Science Translational Medicine

Circulating Tumor Cells and Circulating Tumor DNA

(2011) Catherine Alix-Panabières et al.   Annual Review of Medicine

Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas

(2011) K. Taniguchi et al.   CLINICAL CANCER RESEARCH

Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer

(2011) Cecily P. Vaughn et al.   GENES CHROMOSOMES & CANCER

Detection and quantification of rare mutations with massively parallel sequencing

(2011) I. Kinde et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma

(2011) C. Bettegowda et al.   SCIENCE

Exploring the Genomes of Cancer Cells: Progress and Promise

(2011) M. R. Stratton   SCIENCE

Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development

(2011) J. Wu et al.   Science Translational Medicine

CA125—A Test with a Change of Heart

(2010) Kenneth A. Sikaris   Heart Lung and Circulation

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Advances in understanding cancer genomes through second-generation sequencing

(2010) Matthew Meyerson et al.   NATURE REVIEWS GENETICS

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip

(2010) S. L. Stott et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing

(2010) R. J. Leary et al.   Science Translational Medicine

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

(2009) F Loupakis et al.   BRITISH JOURNAL OF CANCER

Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer

(2009) Y. Kuang et al.   CLINICAL CANCER RESEARCH

Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations

(2009) Matthias Holdhoff et al.   JNCI-Journal of the National Cancer Institute

Biomarkers in colorectal cancer: added value or just added expense?

(2008) Leonard B Saltz   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

The cancer biomarker problem

(2008) Charles L. Sawyers   NATURE

Circulating mutant DNA to assess tumor dynamics

(2008) Frank Diehl et al.   NATURE MEDICINE

Detection of Mutations inEGFRin Circulating Lung-Cancer Cells

(2008) Shyamala Maheswaran et al.   NEW ENGLAND JOURNAL OF MEDICINE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE